Abstract:OBJECTIVE:To evaluate the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) once every 4 weeks by subcutaneous administration on hemoglobin (Hb) maintenance in dialytic patients with chronic renal anemia who had been treated with stable dose of erythropoietin (EPO). METHODS:This was an open, randomized, controlled, multi-center trial. All the hemodialysis or peritoneal dialytic patients in EPO maintenance treatment received subcutaneous EPO-β during the 6-week pre-treatment period to maintain Hb level between 100 g/L and 120 g/L. Eligible patients were randomized (2:1) to accept either C.E.R.A. once every 4 weeks by subcutaneous administration (C.E.R.A. group, n = 187) or subcutaneous EPO-β 1-3 times weekly (EPO group, n = 94) for 28 weeks (including 20-week dose titration period and 8-week efficacy evaluation period). The starting dose of C.E.R.A. was converted according to the dose of EPO-β administered in the week preceding the first study drug administration. The primary outcome was the change of Hb level between the baseline and that in the efficacy evaluation period. RESULTS:Totally 253 patients completed the whole 28-week treatment. The change of baseline-adjusted mean Hb was +2.57 g/L for C.E.R.A. group and +1.23 g/L for EPO group, resulting in a treatment difference of 1.34 g/L (95%CI -1.11 - 3.78 g/L). Since the lower limit of 95%CI was greater than the pre-defined non-inferiority margin -7.5 g/L (P < 0.0001), C.E.R.A. once every 4 weeks by subcutaneous administration was clinically non-inferior to EPO regarding the maintenance of stable Hb level. The proportion of patients maintaining Hb level within the range of 100-120 g/L through efficacy evaluation period was similar between the two groups (69.0% for C.E.R.A. group vs 68.9% for EPO group, P > 0.05). The overall incidence of adverse events was similar between the C.E.R.A.(41.7%) and EPO (46.2%) groups (P > 0.05). The safety findings were in accordance with the patients' primary diseases rather than the administration. CONCLUSIONS:Conversion from EPO to C.E.R.A. once every 4 weeks by subcutaneous injection could maintain the Hb in target level in dialytic patients with renal anemia, and it was non-inferior to EPO. In general, subcutaneous administration of C.E.R.A. is well tolerated in dialytic patients with chronic renal anemia.

The Clinical Analysis of L - Carnitine on Maintenance Hemodialysis Patient

Clinical Effect of L-carnitine on Carnitine Deficiency in Maintenance Hemodialysis Patients

Effect of L-carnitine on congestive heart failure in patients on maintenance hemodialysis

Clinical observation of different L-carnitine doses for the treatment of heart failure in maintenance hemodialysis patients

Comparison of Therapeutic Efficiency Between Saccharum Iron and Ferrum Dextran Iron: a Multicenter Clinical Trial

Long-Term Effects of Oral L-Carnitine Supplementation on Anemia in Chronic Hemodialysis

Effect of L-carnitine Supplementation on Anemia and Muscle Strength in Peritoneal Dialysis Patients

Intravenous iron sucrose in maintenance hemodialysis patients: a prospective randomized controlled multi-center clinical trial

[Supplementation with High-Dose L-carnitine on Hemodialysis Tolerance in Uremic Patients with Severe Heart Diseases].

Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial

To Investigate Plasma Levels of Free and Total Carnitine in Patients Undergoing Hemodialysis or Peritoneal Dialysis

The Effects of Oral Vitamin Con Microinflammatory State in Hemodialysis Patients

An Observation of the Treatment of Sidney Anemia By Using Levocarnitine and Erythropoietin

[The Efficacy and Safety of Continuous Erythropoietin Receptor Activator in Dialytic Patients with Chronic Renal Anemia: an Open, Randomized, Controlled, Multi-Center Trial].

Progress in clinical application of levocarnitine in maintenance hemodialysis

The Level and Significance of Serum IL-6,TNF-α and L-carnitine in Hemodialysis Patients

Effects of L-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis

Meta-analysis of levocarnitine for hemodialysis patients with renal anemia

Cross-over Study of Influence of Oral Vitamin C Supplementation on Inflammatory Status in Maintenance Hemodialysis Patients.

Clinical efficacy of L-carnitine in treating diabetic peripheral neuropathy

Efficacy of Intravenous Iron Supplementation in Improving Anemia in Patients Undergoing Maintenance Hemodialysis